|Table of Contents|

Discordant expression of estrogen receptor(ER)，progestin receptor(PR) and Her-2 between primary and metastatic breast cancer and effect on clinical treatment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
592-595
Research Field:
Publishing date:

Info

Title:
Discordant expression of estrogen receptor(ER)，progestin receptor(PR) and Her-2 between primary and metastatic breast cancer and effect on clinical treatment
Author(s):
Yang Ying1; Chen Feng2; Ni Guoying1; Ding Gang3
1.Department of Oncology;2.Department of Pathology,Chongming Branch,Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine,Shanghai 202150,China;3.Department of Oncology,Shanghai International Medical Center,Shanghai 200120,China.
Keywords:
breast cancer; primary site; metastatic site; ER; PR; Her-2; discordant expression
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.04.015
Abstract:
Objective：To explore discordant expression of estrogen receptor(ER)，progestin receptor(PR) and Her-2 between primary and metastatic breast cancer and to detect effect on clinical treatment.Methods:44 cases of breast cancer with lymph nodes metastasis or distant metastasis or local relapse were detected expression of ER,PR and Her-2 by immunohistochemistry assay.Then to object expression rates and gifting rates of ER,PR and Her-2 in primary and metastatic sites of breast cancer.And treatment of patient was changed in clinic due to the expression gifts of ER,PR and Her-2 in primary and metastatic breast cancer.Results:Positive rates of ER,PR and Her-2 were respectively 68.2%，61.4%，18.2% in primary sites of breast cancer,and 65.9%，63.6%，9.1% in metastatic sites.Positive rates of ER,PR and Her-2 were no significant different between primary and metastatic sites.Total discordant rates of ER,PR and Her-2 were 25.0%（11 cases），27.3%（12 cases），9.1%（4 cases） respectively.Endocrine treatment was added in 12 patients（12/44,about 27.3%).Conclusion:ER,PR and Her-2 were discordant between primary and metastatic breast cancer,so to detect ER,PR and Her-2 of metastatic sites again was necessary,and design clinic treatment according to expression of receptors in primary and metastatic breast cancer.

References:

[1]Sotiriou C,Neo SY,McShane LM,et al.Breast cancer classification and prognosis based on gene expression profiles from a population-based study［J］.Proc Natl Acad Sci USA,2003(100):10393-10398.
[2]Rouzier R,Perou CM,Symmans WF,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy［J］.Clin Cancer Res,2005(11):5678-5685.
[3]Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications［J］.Proc Natl Acad Sci USA,2001(98):10869-10874.
[4]Franco A，Co LN,Chlebonski NT.Discordance in estrogen and progestin receptor status between primary metastatic breast cancer［C］.ASCO,2004:539-540.
[5]Broom ＲJ，Tang PA，Simmons C，et al．Changes in estrogen receptor（EＲ)，progesterone receptor（PＲ) and HEＲ2/neu status with time:Discordance rates between primary and metastatic breast pathology samples［J］．Anticancer Ｒes， 2009， 29(5):1557-1562.
[6]Jacot W,Pouderoux S,Bibeau F,et al.Hormone receptors and HER-2 changes during breast cancer progression:Clinical implications［J］.Bull Cancer,2011,98(9):1059-1070.
[7]Erdem GU,Altundag K,Ozdemir NY,et al.Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer［J］.J BUON,2017,22(2):365-376.
[8]Zhu YY,Si W,Ji TF,et al.The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients［J］.Tumour Biol,2016,37(6):7675-7684.
[9]Shiino S,Kinoshita T,Yoshida M,et al.Prognostic impact of discordance in hormone receptor status between primary and recurrent sites in patients with recurrent breast cancer［J］.Clin Breast Cancer,2016,16(4):e133-140.
[10]Mu YX,Zhang P,Ma F,et al.Clinical outcome of receptor expression discordance between primary and metastatic breast cancer［J］.Chinese Journal of Oncology,2018,40(7):506-511.
[11]Mark N Jabbour，Cleo Y Massad，Fouad I Boulos.Variability in hormone and growth factor receptor expression in primary versus recurrent,metastatic,and post-neoadjuvant breast carcinoma［J］.Breast Cancer Research and Treatment,2012,135(1):29-37.
[12]Yeung C,Hilton J,Clemons M,et al.Estrogen,progesterone,and HER2/neu receptor discordance between primary and metastatic breast tumours-a review［J］.Cancer Metastasis Rev,2016,35(3):427-437.
[13]Anand AS,Velayudhan ST.Discordance of estrogen & progesterone receptors after neoadjuvant chemotherapy in breast cancer-an indian study［J］.Indian J Surg Oncol,2016,7(3):316-369.
[14]Jin X,Jiang YZ,Chen S,et al.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients:A prospective observational study［J］.Oncotarget,2015,6(11):9600-9611.
[15]Tural D,Karaca M,Zirtiloglu A,et al.Receptor discordances after neoadjuvant chemotherapy and their effects on survival［J］.J BUON,2019,24(1):20-25.
[16]Guarneri V,Dieci MV,Barbieri E,et al.Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients［J］.Ann Oncol,2013,24(12):2990-2994.
[17]G Cancello,P Maisonneuve,N Rotmensz,et al.Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse［J］.Annals of Oncology,2013,24(3):661-668.
[18]Matsumoto A,Jinno H,Murata T,et al.Prognostic implications of receptor discordance between primary and recurrent breast cancer［J］.Int J Clin Oncol,2015,20(4):701-708.
[19]Yang YF,Liao YY,Yang M,et al.Discordances in ER,PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients［J］.Med Oncol,2014,31(10):214.
[20]JIN Guanghua,FAN Ying,LI Zihao.Hormone receptors change after neoadjuvant chemotherapy in breast cancer and their effects on postoperative endocrine therapy［J］.Progression of Modern General Surgery in China,2017,20(1):22-26.［金光华，范莹，李子豪.乳腺癌新辅助化疗前后激素受体变化对术后内分泌治疗的影响［J］.中国现代普通外科进展,2017，20(1)： 22-26.］
[21]Meng X,Song S,Jiang ZF,et al.Receptor conversion in metastatic breast cancer:A prognosticator of survival［J］.Oncotarget,2016,7(44):71887-71903.

Memo

Memo:
上海市崇明区科研攻关计划项目(编号：CKY2013-35)
Last Update: 2019-12-26